Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Protein & Peptide Letters
Title:Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Volume: 20 Issue: 4
Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese and Giovanni Vitale
Affiliation:
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Abstract: Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Export Options
About this article
Cite this article as:
Caraglia Michele, Dicitore Alessandra, Marra Monica, Castiglioni Sara, Persani Luca, Sperlongano Pasquale, Tagliaferri Pierosandro, Abbruzzese Alberto and Vitale Giovanni, Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040005
DOI https://dx.doi.org/10.2174/0929866511320040005 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells
Medicinal Chemistry Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters Stem Cells and Bioactive Scaffolds as a Treatment for Traumatic Brain Injury
Current Stem Cell Research & Therapy MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Lactones: Generic Inhibitors of Enzymes?
Mini-Reviews in Medicinal Chemistry Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design The Leukocyte Common Antigen-Related Protein LAR: Candidate PTP for Inhibitory Targeting
Current Topics in Medicinal Chemistry The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine